Somatic TP53 mutations characterize preleukemic stem cells in acute myeloid leukemia
Ridhima Lal, Heinz Sill(Medical University of Graz), Sybille Hofer(Medical University of Graz), Vendula Švendová(Medical University of Graz), Peter Ulz(Freenome (United States)), Eduard Schulz(Medical University of Graz), Birgit Feilhauer, Kristina Aubell(Institute of Human Genetics), Karl Kashofer(Medical University of Graz), Jan Moritz Middeke(Fresenius (Germany)), Armin Zebisch(Medical University of Graz), Konstanze Döhner(University Hospital Ulm), Frank G. Rücker(University Hospital Ulm), Albert Wölfler(Medical University of Graz), Ellen Heitzer(Medical University of Graz), Michael G. Schimek(University of Graz), Gerald Höefler(Medical University of Graz), Angelika Rosenberger, Beate Rinner(Medical University of Graz), K. Lind(Medical University of Graz), Christian Thiede(University Hospital Carl Gustav Carus)
Cited by 56
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k